The antibody-drug conjugate, sacituzumab govitecan, is a treatment for patients with metastatic triple-negative breast cancer, currently under priority review by the FDA for accelerated approval. If approved, sacituzumab govitecan would be the first therapy approved for this patient group.

The drug-linker CL2A-SN-38 is a critical component in the novel antibody-drug conjugate. This key constituent is being produced at JM's Devens, MA facility. Immunomedics has significantly scaled the ongoing partnership due to JM's track-record in high potency GMP manufacturing and proven chemical and analytical development for scale-up and production of complex molecules.

'We are proud to build on our existing relationship with Immunomedics to enable the production of viable treatment options to improve cancer patients' lives,' said Nick Shackley, Vice President, Health. 'This long-term master supply agreement signifies our continuing dedication to help companies deliver novel treatments and medicines, to create a healthier world.'

Attachments

  • Original document
  • Permalink

Disclaimer

Johnson Matthey plc published this content on 09 January 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 09 January 2019 15:33:05 UTC